Yu Wang

Yu Wang

Auto-generated profile, based on publicly available information

Yu Wang

Huazhong University of Science and Technology

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2026 in Cell Transplantation
Verified
Journal Article
Open access
YWYu Wang
Yu Wang
JWJiaying Wu
Jiaying Wu
XHXiaobing Huang
Xiaobing Huang
YXYi Xiao
Yi Xiao
Chronic active Epstein–Barr virus (CAEBV) infection is a rare and highly lethal lymphoproliferative disorder. The pathological basis of this condition involves Epstein–Barr virus (EBV) persisting in hematopoietic stem cells, driving clonal expansion of T cells or natural killer (NK) cells, and subsequently triggering systemic inflammatory responses and multi-organ failure. Current treatment modalities, encompassing antiviral medications, immunosuppressants, and cytotoxic chemotherapy, offer only transient remissions, with the majority of patients ultimately experiencing relapse. Recent single-cell sequencing and chimera studies have confirmed that EBV-infected hematopoietic stem cells constitute the “seed” cell population for CAEBV initiation and maintenance. This finding indicates that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment known to date that can fully eradicate viral reservoirs and restore normal immunity, suggesting that it may represent a curative strategy. Nevertheless, transplantation timing, donor matching, conditioning intensity, and transplant-related complications have been shown to have a significant impact on long-term prognosis. The clinical decision-making process necessitates a high degree of individualization, incorporating molecular risk factors, disease activity, and comorbidities. Advancing research into the latent-lytic cycle regulation mechanisms of EBV, in addition to the clinical translation of small-molecule inhibitors targeting viral proteins and EBV-specific adoptive cell therapies, holds great promise for the future. One such potential avenue for future research is the development of an integrated “pre-transplant viral load reduction-post-transplant relapse prevention” strategy. This approach shows great potential in reducing transplant-related mortality and continuously improving survival outcomes for CAEBV patients.

31 December 2025 in Immunotherapy Advances
Verified
Journal Article
Open access
YWYu Wang
Yu Wang
JWJiaying Wu
Jiaying Wu
XHXiaobing Huang
Xiaobing Huang
YXYi Xiao
Yi Xiao
Acute myeloid leukemia (AML) is a clonal malignant disease that arises from hematopoietic stem cells and is characterized by high genetic heterogeneity. AML has a poor prognosis, with a low 5-year survival rate, and is typically treated with chemotherapy. The management of AML, particularly for cases that are relapsed or refractory to conventional chemotherapy and transplantation, remains a formidable clinical challenge. This comprehensive review systematically evaluates the current landscape of cellular immunotherapeutic strategies for AML. We focus on the mechanisms of action, recent clinical progress, and persistent challenges associated with a range of adoptive cell therapies. These include natural killer cell-based infusions, and engineered approaches such as chimeric antigen receptor-T, CAR-NK, and CAR-macrophage therapies. Furthermore, we examine the roles of tumor-infiltrating lymphocytes and cytokine-induced killer cells. Our analysis synthesizes evidence from preclinical studies and clinical trials to assess the potential of these modalities in inducing durable antileukemic responses. We conclude that while cellular immunotherapies represent a transformative frontier in AML treatment, their broad application is currently constrained by target antigen heterogeneity, a complex tumor microenvironment, and significant toxicities. Finally, this review discusses strategic innovations necessary to overcome these barriers, highlighting directions for future research aimed at enhancing the efficacy and safety of these promising treatments for AML patients.

18 October 2026 in Cell Transplantation
Verified
Journal Article
Open access
YWYu Wang
Yu Wang
XZXumeng Zhao
Xumeng Zhao
MZMi Zhou
Mi Zhou
YXYi Xiao
Yi Xiao
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only treatment with curative potential for myelodysplastic syndromes (MDS). This review synthesizes MDS-specific evidence on transplant indication and timing, conditioning, donor choice, molecular predictors, and post-transplant surveillance. Prospective biologic-assignment studies support a survival benefit in fit older adults with higher-risk MDS. The Molecular International Prognostic Scoring System (IPSS-M), transplant-specific cytogenetic and mutational factors, comorbidity, and transfusion burden refine selection beyond the Revised International Prognostic Scoring System (IPSS-R). Alternative donors expand access, including haploidentical transplantation with post-transplant cyclophosphamide. Conditioning intensity should reflect both disease risk and patient fitness, with regimen-level scoring emerging for cord blood transplantation. Although non-relapse mortality has decreased over time, relapse remains the major unresolved cause of failure. MDS-specific measurable residual disease, graft-versus-host disease, cytomegalovirus assessment, and risk-adapted post-transplant interventions provide a practical framework for individualized care.

1 October 2026 in Cell Transplantation
Verified
Journal Article
Open access
YWYu Wang
Yu Wang
YXYi Xiao
Yi Xiao
Chronic ocular graft-versus-host disease is a frequent and potentially sight-threatening complication of allogeneic hematopoietic stem cell transplantation. Dry eye is a major manifestation within a broader disorder involving lacrimal and meibomian glands, conjunctiva, corneal epithelium, and sensory nerves. This narrative review examines clinical assessment, tissue injury, and treatment, with particular attention to recent experimental and translational studies. Human ocular evidence is distinguished from systemic chronic graft-versus-host disease outcomes, findings in other dry-eye populations, and preclinical observations. Single-cell profiling and experimental studies implicate altered epithelial–immune interactions, regulated cell death, oxidative stress, and fibrotic remodeling. Their relevance to treatment selection in patients remains to be established. Clinical care combines tear replacement and conservation, local immunomodulation, epithelial protection, management of meibomian gland dysfunction, and visual rehabilitation. Systemic treatment decisions require separate consideration of ocular activity and other organ involvement. We propose a framework that relates inflammatory activity, structural damage, and dominant ocular traits to management options. This framework is an author-proposed conceptual synthesis, not a validated staging system or treatment algorithm. Small cohorts, inconsistent definitions, attrition, and concurrent therapies limit comparative conclusions. Future trials need standardized ophthalmic endpoints, assessment of treatment burden, and validation of biomarkers before these can guide individual treatment decisions.